ICARE Social Media Post October 2020

New ASCO Guidelines On Use Of PARP Inhibitors To Manage Ovarian Cancer

New guidelines for the use of PARP inhibitors to treat ovarian cancer among those with BRCA1 or BRCA2 mutations were published through the American Society of Clinical Oncology (ASCO) to guide providers about the role of this class of drugs in the management of this type of cancer.

Link to the guidelines are available at: https://ascopubs.org/doi/full/10.1200/JCO.20.01924

Permanent link to this article: https://inheritedcancer.net/post101320/